• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Botswana: AstraZeneca Vaccines Arrives in Botswana

firstwordpharmaAugust 09, 2021

Tag: Botswana , AstraZeneca , Vaccine

Government of Botswana this afternoon received 38 400 doses of the AstraZeneca vaccine. The consignment has been purchased by the government through the COVAX facility. Part of this consignment will be used as second dose for those who were previously informed that their second doses were not available. According to a press statement from the Ministry of Health and Wellness, District Health Management Teams (DHMTs) across the country will advise all those concerned in their respective areas, on when they could come for their second dose.

Previous:Three Lakes Foundation, Lung Foundation Australia and Centre of Research Excellence in PF join forces to create a global network for PF research

Next:Additional COVID-19 treatment for Australia

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Botswana: AstraZeneca Vaccines Arrives in Botswana | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Hualan Biological Influenza Vaccine(Split Virion),Inactivated

Hualan Biological Influenza Vaccine(Split Virion),Inactivated
trivalent flu vaccine

trivalent flu vaccine
H7N9 Inactivated Influenza Vaccine-HUALAN

H7N9 Inactivated Influenza Vaccine-HUALAN
Rabies Vaccine(Vero Cell)for Human use

Rabies Vaccine(Vero Cell)for Human use
Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio

Hualan H7N9 Inactivated Influenza Vaccine by Hualan Bio
Hualan Quadrivalent Influenza Vaccine

Hualan Quadrivalent Influenza Vaccine
Poultry Vaccine Series

Poultry Vaccine Series
High purity and quality Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)

High purity and quality Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)
hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

hualan bio Group ACYW135 Meningococcal Polysaccharide Vaccine according to WHO recommended standard

Animal Vaccine Filling Line

Animal Vaccine Filling Line

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service